iifl-logo-icon 1

Neuland Laboratories Ltd Share Price

8,165
(-3.71%)
Jul 19, 2024|09:44:51 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open8,400
  • Day's High8,449.8
  • 52 Wk High8,650
  • Prev. Close8,479.45
  • Day's Low8,137.35
  • 52 Wk Low3,120
  • Turnover (lac)413.96
  • P/E36.23
  • Face Value10
  • Book Value994.26
  • EPS233.75
  • Mkt. Cap (Cr.)10,475.6
  • Div. Yield0.17
No Records Found

Neuland Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

8,400

Prev. Close

8,479.45

Turnover(Lac.)

413.96

Day's High

8,449.8

Day's Low

8,137.35

52 Week's High

8,650

52 Week's Low

3,120

Book Value

994.26

Face Value

10

Mkt Cap (₹ Cr.)

10,475.6

P/E

36.23

EPS

233.75

Divi. Yield

0.17

Neuland Laboratories Ltd Corporate Action

10 May 2024

12:00 AM

BookCloser

arrow

11 May 2023

12:00 AM

AGM

Announcement Date: 11 May, 2023

arrow

23 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

10 May 2024

12:00 AM

Dividend

Dividend Amount: 14

arrow

Neuland Laboratories Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Neuland Laboratories Ltd SHAREHOLDING SNAPSHOT

20 Jul, 2024|10:29 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 32.72%

Non-Promoter- 32.51%

Institutions: 32.51%

Non-Institutions: 34.76%

Custodian: 0.00%

Share Price

Neuland Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

12.9

12.9

12.9

12.9

Preference Capital

0

0

0

0

Reserves

1,263.64

975.46

822.67

768.98

Net Worth

1,276.54

988.36

835.57

781.88

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2019

Revenue

951.07

936.91

762.71

666.82

yoy growth (%)

1.51

22.83

14.37

26.43

Raw materials

-422.13

-438.41

-380.19

-366.24

As % of sales

44.38

46.79

49.84

54.92

Employee costs

-175.75

-144.02

-118.48

-104.47

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2019

Profit before tax

81.73

104.96

52.49

19.83

Depreciation

-49.03

-39.67

-31.27

-25.86

Tax paid

-18.2

-24.66

-36.61

-3.69

Working capital

83.75

-74.79

43.14

0.41

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2019

Growth matrix (%)

Revenue growth

1.51

22.83

14.37

26.43

Op profit growth

-2.9

44.33

75.33

15.66

EBIT growth

-22.48

65.87

108.65

9.35

Net profit growth

-20.87

405.63

-1.63

36.71

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,558.58

1,191.2

951.08

936.91

762.71

Excise Duty

0

0

0

0

0

Net Sales

1,558.58

1,191.2

951.08

936.91

762.71

Other Operating Income

0

0

0

0

0

Other Income

12.54

9.75

2.08

16.1

3.89

Neuland Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Neuland Laboratories Ltd

Management

Register Office

Registrar Office

Executive Chairman

D R Rao

Non Executive Director

Christopher M Cimarusti

Vice Chairman & CEO

D Sucheth Rao

Vice Chairman & M.D.

D Saharsh Rao

Company Sec. & Compli. Officer

Sarada Bhamidipati

Independent Director

Nirmala Murthy

Independent Director

Homi Rustam Khusrokhan

Independent Director

Prasad R Menon

Independent Director

Sugata Sircar

Independent Director

Pallavi Joshi Bakhru

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Co
Read More

Company FAQs

What is the Neuland Laboratories Ltd share price today?

Down Arrow

The Neuland Laboratories Ltd shares price on N/A is Rs.₹8153.45 today.

What is the Market Cap of Neuland Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd is ₹10460.79 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Neuland Laboratories Ltd?

Down Arrow

The PE and PB ratios of Neuland Laboratories Ltd is 36.23 and 8.52 as of 19 Jul ‘24

What is the 52 Week High and Low of Neuland Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Neuland Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Neuland Laboratories Ltd is ₹3100.05 and ₹8649 as of 19 Jul ‘24

What is the CAGR of Neuland Laboratories Ltd?

Down Arrow

Neuland Laboratories Ltd's CAGR for 5 Years at 75.06%, 3 Years at 57.51%, 1 Year at 166.82%, 6 Month at 48.62%, 3 Month at 10.62% and 1 Month at 30.48%.

What is the shareholding pattern of Neuland Laboratories Ltd?

Down Arrow

The shareholding pattern of Neuland Laboratories Ltd is as follows:
Promoters - 32.72 %
Institutions - 32.52 %
Public - 34.76 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.